Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

NMR reveals a dynamic allosteric pathway in thrombin.

Handley LD, Fuglestad B, Stearns K, Tonelli M, Fenwick RB, Markwick PR, Komives EA.

Sci Rep. 2017 Jan 6;7:39575. doi: 10.1038/srep39575.

2.

Large-scale molecular dynamics simulation: Effect of polarization on thrombin-ligand binding energy.

Duan LL, Feng GQ, Zhang QG.

Sci Rep. 2016 Aug 10;6:31488. doi: 10.1038/srep31488.

3.

Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function.

Yeh CH, Stafford AR, Leslie BA, Fredenburgh JC, Weitz JI.

PLoS One. 2016 Jun 15;11(6):e0157471. doi: 10.1371/journal.pone.0157471.

4.

Protease-activated receptors in hemostasis.

Nieman MT.

Blood. 2016 Jul 14;128(2):169-77. doi: 10.1182/blood-2015-11-636472. Review.

PMID:
27127302
5.

The Fragment 1 Region of Prothrombin Facilitates the Favored Binding of Fragment 12 to Zymogen and Enforces Zymogen-like Character in the Proteinase.

Bradford HN, Krishnaswamy S.

J Biol Chem. 2016 May 20;291(21):11114-23. doi: 10.1074/jbc.M116.723072.

PMID:
27013660
6.

Kinetic dissection of the pre-existing conformational equilibrium in the trypsin fold.

Vogt AD, Chakraborty P, Di Cera E.

J Biol Chem. 2015 Sep 11;290(37):22435-45. doi: 10.1074/jbc.M115.675538.

7.

Promiscuous and specific recognition among ephrins and Eph receptors.

Dai D, Huang Q, Nussinov R, Ma B.

Biochim Biophys Acta. 2014 Oct;1844(10):1729-40. doi: 10.1016/j.bbapap.2014.07.002.

8.

Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis.

Mumaw MM, de la Fuente M, Noble DN, Nieman MT.

J Thromb Haemost. 2014 Aug;12(8):1331-41. doi: 10.1111/jth.12619.

9.

Targeting the GPIbα binding site of thrombin to simultaneously induce dual anticoagulant and antiplatelet effects.

Mehta AY, Thakkar JN, Mohammed BM, Martin EJ, Brophy DF, Kishimoto T, Desai UR.

J Med Chem. 2014 Apr 10;57(7):3030-9. doi: 10.1021/jm4020026.

10.

GpIbα interacts exclusively with exosite II of thrombin.

Lechtenberg BC, Freund SM, Huntington JA.

J Mol Biol. 2014 Feb 20;426(4):881-93. doi: 10.1016/j.jmb.2013.11.027.

11.

Essential role of conformational selection in ligand binding.

Vogt AD, Pozzi N, Chen Z, Di Cera E.

Biophys Chem. 2014 Feb;186:13-21. doi: 10.1016/j.bpc.2013.09.003. Review.

12.

Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin.

Arachiche A, Mumaw MM, de la Fuente M, Nieman MT.

J Biol Chem. 2013 Nov 8;288(45):32553-62. doi: 10.1074/jbc.M113.472373.

13.

The transition of prothrombin to thrombin.

Krishnaswamy S.

J Thromb Haemost. 2013 Jun;11 Suppl 1:265-76. doi: 10.1111/jth.12217. Review.

14.

Designing allosteric regulators of thrombin. Exosite 2 features multiple subsites that can be targeted by sulfated small molecules for inducing inhibition.

Sidhu PS, Abdel Aziz MH, Sarkar A, Mehta AY, Zhou Q, Desai UR.

J Med Chem. 2013 Jun 27;56(12):5059-70. doi: 10.1021/jm400369q.

15.

Correlated motions and residual frustration in thrombin.

Fuglestad B, Gasper PM, McCammon JA, Markwick PR, Komives EA.

J Phys Chem B. 2013 Oct 24;117(42):12857-63. doi: 10.1021/jp402107u.

16.

Ligand binding to anion-binding exosites regulates conformational properties of thrombin.

Malovichko MV, Sabo TM, Maurer MC.

J Biol Chem. 2013 Mar 22;288(12):8667-78. doi: 10.1074/jbc.M112.410829.

17.

Effect of zymogen domains and active site occupation on activation of prothrombin by von Willebrand factor-binding protein.

Kroh HK, Bock PE.

J Biol Chem. 2012 Nov 9;287(46):39149-57. doi: 10.1074/jbc.M112.415562.

18.

Meizothrombin is an unexpectedly zymogen-like variant of thrombin.

Bradford HN, Krishnaswamy S.

J Biol Chem. 2012 Aug 31;287(36):30414-25. doi: 10.1074/jbc.M112.394809.

19.

Conformational selection in trypsin-like proteases.

Pozzi N, Vogt AD, Gohara DW, Di Cera E.

Curr Opin Struct Biol. 2012 Aug;22(4):421-31. doi: 10.1016/j.sbi.2012.05.006. Review.

20.

Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants.

Jadhav MA, Lucas RC, Goldsberry WN, Maurer MC.

Biochim Biophys Acta. 2011 Dec;1814(12):1955-63. doi: 10.1016/j.bbapap.2011.07.012.

Items per page

Supplemental Content

Support Center